The goal of tumor immunology is to understand the interactions between tumor cells and immune system, and ultimately to devise immune basedapproaches to fight cancer. We discuss here recent advances in tumor immunology and in the interaction between immunology and informatics that provide new perspectives for the development of cancer therapy. Cancer immunoprevention is a novel approach to cancer prevention through the use of vaccines and other immunological strategies to be applied before tumor onset. The efficacy of cancer immunoprevention has been demonstrated in several experimental systems, however, as frequently happens in novel approaches, cancer immunoprevention studies incorporate a large number of variables. We show here how a specifically designed lattice gas model can provide significant insight for the analysis of immune variables and the design of new biological experiments. A second approach that provides new perspectives in tumor immunology as the result of interactions between immunology and informatics is the use of DNA microarrays to investigate and monitor tumor-host relationships and modifications induced by immunopreventive and immunotherapeutic interventions.
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TUMOR IMMUNOLOGY TODAY
We will discuss here some recent advances in basic and clinical tumor immunology that have significantly changed our mindframe and that have not yet fully obtained the attention of immunoinformatics.
One of the oldest problems at the foundation of tumor immunology was finally solved thanks to the use of genetically modified murine models. The problem is deceivingly simple: the main function of the immune system is to defend the host from pathogenic microorganisms. Is defense from tumors also a function of the immune system? In principle the experiments to answer this question are straightforward: measure spontaneous and/or carcinogen-induced tumor incidence in immunodeficient individuals and compare with tumor incidence in matched immunocompetent subjects.
Earlier attempts at performing this type of experiment were largely inconclusive because the available mouse models were not truly immunodeficient, especially at the older ages required to investigate spontaneous tumor incidence. A major revolution for tumor immunology, and for many others fields of investigation, was the advent of genetically engineered mice. It is now possible to address the issue of tumor development in mice that carry "designer" types immunodeficiency and are constantly immunodepressed throughout their life. The results were very clear and convincing: immunodeficient mice are indeed more prone to carcinogenesis (both spontaneous and carcinogen-induced) than immunocompetent mice [1] . The study of tumors arising in immunodeficient mice showed also a further relevant issue. When compared in immunocompetent mice, tumors originally arising in immunocompetent mice were poorly immunogenic, whereas those of immunodeficent mice were immunogenic. The reason is that the immune system eliminates nascent immunogenic tumors, whereas tumors that escape immune surveillance do so because they have lost or downmodulated recognition elements. Thus the immune system "edits" tumor immunogenicity, a phenomenon now called "immunoediting" [1] . The overall conclusions are now very clear: control of tumor growth is a physiological function of the immmune system, but tumors can escape immune surveillance through a downmodulation of their immunogenicity. One important consequence of the issues discussed above was the idea that a targeted activation of the immune system before tumor onset, or during preneoplastic stages, could be a new type of cancer prevention (see below) [2] .
Another important new sector of investigation is that of cell populations that negatively regulate immune responses. For more than two decades the research was fruitless, or worse led to false paths, to the point that "suppressor" became a dirty word in immunology. Now we have two bona fide new cell types that negatively regulate immune responses in general and against cancer. One is a T cell expressing CD4 and CD25 surface markers. When this cell population of regulatory T cells (Treg) is temporarily inhibited before administration of a vaccine the ensuing immune responses are boosted. The second population is of myeloid origin and displays CD11b and Gr1 surface markers. Myeloid cells are frequently induced by tumor growth, thus explaining the state of profound immunodepression that accompanies the late stages of neoplastic development. For the sake of the discussion of informatic models of antitumor responses, it must be noted that current models do not take into account such regulatory cell populations, but frequently limit themselves to a natural decay of the immune responses with time.
A third important lesson for tumor immunology comes from clinical applications of immune strategies for the cancer therapy. Tumor immunology is traditionally dominated by T cells and by strategies ultimately aimed at activating cytotoxic T cells (CTL) that can destroy tumor cells. Antibodies and B cells are usually disregarded, because tumor cells are mostly resistant to lysis by antibodies and complement. If one now looks at which strategies effectively made the transition from the laboratory to the clinics the picture is completely different. The only immunological "drugs" approved by regulatory agencies (such as the US FDA) for clinical use against cancer are monoclonal antibodies and cytokines, whereas T cell targeted strategies (e.g. vaccines and dendritic cells) were poorly effective and are still at an early stage of clinical development.
One of the reasons for the clinical success of antibodies and cytokines is undoubtedly their marketability in a format more akin to traditional drugs, hence more suited to standard practices of clinical oncology. Apart from that, the reason is very simple: antibodies make effective anticancer drugs that demonstrated their efficacy against solid tumors and hematopoietic malignancies, either as single treatments, or in combination with cytotoxic drugs. In addition to those already in clinical use we expect to see many more monoclonal antibodies to enter the clinical arena in the next few years.
The Future of Tumor Immunology
Even though the clinical results in the past were far from encouraging, we are not going to see a reduction in the attempts at inducing anti-tumor CTLs in the future. At present most attempts are based on dendritic cells (DC) that are taken from patients, loaded in vitro with antigens, then reinjected in vivo to present the antigen to T cells. There is ample space to improve DC-based vaccines, however current results are, again, not spectacular [3] . The next wave of cancer immunotherapy will probably include attempts at inhibiting regulatory cells, to improve the efficacy of therapeutic vaccines. Preclinical results are certainly encouraging [4] .
One major stumbling block for cancer immunotherapy is that it is usually tested in advanced cancer patients. This is a reasonable setup for early trials of new cytotoxic drugs that directly hit cancer cells, however it is not adequate for immune strategies that require the presence of a functioning, not heavily depressed immune system. To avoid this problem most tumor immunologists are striving and campaigning to move clinical trials to enroll less advanced patients, ideally patients bearing only a minimal residual disease, against which the immune system should be less disadvantaged. From the point of view of models this will have the additional advantage of a clinical situation more similar to the ones that are modeled in vivo and in silico.
In the experimental environment the trend to move immune intervention to early stages of tumor development is taking even more extreme incarnations. Recently it has been shown that prophylactic vaccines administered to transgenic mice prone to cancer development can completely prevent tumor onset and restore a normal life expectancy [5, 6] . Even though prophylactic cancer vaccines are still far from human application, this opens up an entirely new perspective in cancer prevention, leading to a future in which vaccines will equally contribute to the prevention of infectious diseases and cancer.
It is interesting to note that mouse models reveal a significant contribution of antibodies and cytokines likeinterferon in long-term cancer prevention, whereas CTLs appear to play a negligible role [7] . Such results were mainly obtained in transgenic mouse models harboring a specific oncogene, HER-2/neu, expressed also by various human cancers. The investigator reexamined the role of the target antigen and its relationship with immune responses effective in preventing tumor onset. The success in cancer immunoprevention [8] were attributed to two main reasons: a) HER-2/neu was at the same time the target antigen and the oncogene driving carcinogenesis, and b) HER-2/neu is expressed on the cell surface, hence it is recognized and bound both by T cells, in the form of MHC-bound peptides, and by antibodies as a native surface protein. The first condition makes HER-2/neu indispensable for tumor growth, and minimizes the emergence of antigen-loss variants that are common for tumor antigens not involved in the maintenance of the neoplastic state. The second condition ensures that HER-2/neu remains recognizable also in MHC loss variants that frequently emerge in all tumor types [9] .
It is interesting to note that HER-2/neu is one of the few antigens fulfilling both criteria. Most other tumor antigens are not involved in carcinogenic processes, and tumor cells can easily down regulate antigenic expression without consequence for their tumorigenicity. Several other tumor antigens are not expressed on the cell surface and can be recognized solely as MHC-bound peptides, or not at all if the tumor cell loses MHC expression. It follows that most members of the current database of tumor antigens are not suitable targets for cancer immunoprevention, or in general for antibody based strategies. This opens a new field of investigation for modeling in vivo, in vitro and in silico, to search for new target antigens suitable for cancer immunoprevention that are at once indispensable for tumor growth and localized on the cell membrane.
MODELLING CANCER-IMMUNE SYSTEM COM-PETITION
In dealing with modelling of the interaction and competition between the immune system and cancer cells one should be aware that the Cancer -Immune system competition can play a crucial role besides therapeutical actions. The above mentioned competition may possibly end up with the elimination of the cancer cells, or the progressive invasion by cancer cells of other tissues or organs. The goal of medical treatments is to improve the immune response by activating the immune defence and/or specializing the ability of immune cells to identify the presence of the host.
The immune competition is a phenomenon which involves aggressive cells or particles (either external non-self pathogens or self modified or corrupted cells) and the various populations of the immune system. The Immune System appears to be a distributed system which lacks central control, but which, nevertheless, performs its complex task in an extremely effective and efficient way. Complexity, in this framework, is driven by the fact that interactions are developed at different scales (i.e. the cellular dynamics is ruled by subcellular interactions) and different mechanisms operate on the same subject (mechanical for the dynamics and biological for the immune competition). The state of the art of the immune mechanisms from the point of view of molecular biology is described in specialized literature [10] [11] [12] . Owing to the rapid progress of biological knowledge this is rapidly changing.
A model, which is a mapping from a real-world domain to a mathematical domain, highlights some of the essential properties while ignoring others, complicating, ones. A good model must be relevant, capturing the essential properties of the phenomenon, computable, driving computational knowledge into mathematical representation; understandable, offering a conceptual framework for thinking about the scientific domain; and extensible, allowing the discovery of additional real properties in the same mathematical framework. In the framework of Immune system competition relevant means that a model should be able to capture the essential properties of the system, the system entities organization and their dynamic behavior. A computable model should then be able to simulate both the dynamic behavior and the evolution and interactions of the system entities which play the game. An understandable model must reproduce concept and ideas of tumor immunology while opening new computational possibilities for understanding the immune competition. Finally extensible models should allow the inclusion of new knowledge with a limited effort.
The biological system we are dealing with is characterized by a great complexity so that it is very difficult, or even impossible, to develop a detailed mathematical description of all phenomena related to the immune competition which satisfies all the above properties. However, if one focuses the attention on specific type of interaction, one may attempt to develop ad hoc models for specific phenomena at the chosen observation and representation scale. In fact, as usual in any modeling approach, different scales can be selected toward the description of the same phenomenon [13, 14] .
In describing the Immune System one may refer cellular and sub-cellular scales by observing the interaction and competition processes for various cell populations which are effective in the phenomenon under investigation (microscopic scale). Working on this scale one may attempt to model a single cell [15] but it would be practically impossible to describe with such a detail one or more cell population. On the other side if the main interest is the effect of the interactions among cells then one can consider and describe only those effect of cell state modifications which are relevant for the interactions with other entities. In this framework populations are collections of distinguishable individuals so that any global behavior results from individuals actions. Models can be constructed using "single agents" based methods like cellular automata, lattice gas like dynamics or agent technique [13, 16, 17] . On a larger scale (mesoscale) one may consider the evolution of the statistical distribution over the biological activities of the cell populations. On this scale any detailed description of activity at cellular and subcellular scale is lost but may not be neglected. Results will strongly depend on the description that one may include on lower level scales.
Different peculiarities of individuals are included in the statistical distribution over the biological state of the various interacting populations. In this framework modeling is based on mathematical methods which are typical of the kinetic theory of gases [18] , and develops equations which show a substantial similarity with the Boltzmann or Vlasov equations (generalized kinetic (Boltzmann) models [14, 15, 19, 20] ). A macroscopic description (macroscale) of the phenomenon consists in looking at the system by considering each cell population as a whole, while its behavior is observed collectively. In this framework peculiarities of individuals are forgotten (neglected). Interactions between different populations will give rise to the dynamical behavior. In this framework, usually described with systems of ODE (Ordinary Differential Equations), the native complexity is reduced but applied mathematicians have to deal with the problem of identifying the pertinent parameters which may loose biological meaning through the above simplification. In spite of these difficulties many attempts have been made in modeling the Immune System competition. These works are reviewed in many journals and book chapters [21, 22] .
Immunotherapy and immunoprevention use the Immune competition for therapeutical goals. As already pointed the Immune System is very clever in recognizing foreign nonself antigens but gives poor response for self cancer cells. Cancer immuno-therapy and prevention try to overcome this lack of recognition using Tumor Associated Antigens (TAA) and adjuvants (cytokines). When the Immune System recognizes cancer cells as potentially dangerous then the different components (both of the natural and adaptive Immune System) are activated in the game. If this competition is successful the overall effect is a decreasing of the number of tumor cells. This very simple picture does not take into account the various escape mechanisms that prevent the activation or induce the inhibition and suppression of the Immune System.
At macroscopic scale the main interest is to trace the activation of the global immune response and the regression of tumor measured as decreasing number of cancer cells. This knowledge is sufficient in order to understand if and when immunotherapy may be a possible alternative for treatment. To achieve this goal Kischner and Panetta [23] built up a model describing tumor-immune system competition. For their purpose they consider the evolution of three populations: the so called immune effector cells E(t), which include all the Immune System cells and molecules which are effective in killing tumor cells, i.e. TC, Ab, Nk;
the tumor cells T(t);
the concentration I L (t) of cytokine interleukin-2 in the tumor site compartment under examination.
The dynamics of these populations is modeled by a system of three ordinary differential equations which are studied together with initial conditions. The system includes two terms representing treatments and eleven parameters. Conceivable values for these parameters, to be chosen on the basis of experimental suggestions, may be found in the literature. In particular, the value of one parameter, namely c, which represents the antigenicity of the tumor, varies sensibly depending on the patient and on the cancer. The model has been numerically investigated in detail considering both the absence and the presence of different treatments. In the latter case the authors studied three different strategies:
an adoptive cellular immunotherapy; the input of interleukin-2; the combined effect of adoptive cellular immunotherapy and interleukin-2.
The model is able to explain the gross behavior of clinical data and of some experimental evidence but lacks details on the immune response and spatial effects.
A better approach from this point of view is represented by the so-called Generalized Boltzmann Models (kinetic theory) that describe the system at mesoscale level. In this approach the competition between immune cells and aggressive hosts is modeled by methods which are typical of nonequilibrium statistical mechanics [20, 24, 25] . The substantial difference with respect to the equations of the kinetic theory is that the microscopic state of the cells is defined not only by mechanical variables, say position and velocity, but also by an internal biological microscopic state related to the typical activities of the cells of a certain population. Contact interactions and short-range interactions between cells can be described in details and included in the collision part of the equations. This kind of model does also include spatial diffusion of Immune System components and tumor cells in the specified organ. The mathematical structure of the equations is more present but the model strategy includes relevance, understandability and extensibility. In realistic situations computability may become a serious problem. A general description of this approach can be found in the recent paper [26] .
In order to show the properties of the model approach these authors analyze the case of two interacting populations, namely the endothelial cells and the immune cells. Both cells can take two states. Endothelial cells can be normal or progressing (i.e. tumor cells), while immune cells can be inhibited or active. Using an appropriate description of the interactions they recover the relevant description of the Immune competition including the inhibition of immune cells by the tumor. Even if many problems still need to be solved this seems the most promising approach in order to build up a mathematical theory to describe immune competition at mesoscale level.
A microscopic description of the immune competition can be achieved using models based on agent-based method. These methods are nowadays very popular as they find applications in various fields. However the idea of discrete agents whose global dynamics is able to reproduce macroscopic behavior has been introduced since mid last century in the framework of fluid dynamics. In the following section we describe the Lattice Gas approach we used in order to describe the Immune prevention action of a tumor vaccine.
Microscopic Description of Immunoprevention Actions
Discrete methods have been widely used in modeling the Immune System ( [20, 22, 24, 25, 27] for review and [28] [29] [30] for applications in systems biology). This class of techniques allows to describe, in a defined space, the Immune System entities with their different biological states and the interactions between different entities. The Immune System evolution in a 2D-space and in time is generated from the interactions and diffusion of the different entities. The major advantage of this class of techniques is that the entities and the relationships can be described in terms that are more similar to the biological world. The intrinsic non-linearity of the system is treated with no additional efforts. Models based on this class of techniques reproduce the biological knowledge of the system; so they are relevant, understandable and extensible. They are naturally computable but the computational effort increases drastically with increasing biological details (e.g. the immune repertoire). The Lattice Gas Automata (LGA) technique we use in the model described in this section belongs to this class. Their mathematical counterpart could be identified in the Generalized Kinetic Equations referred before.
To describe the cancer -immune system competition one needs to include all the entities (cells, molecules, adjuvants, etc.) which biologist recognize as relevant in the competition. These entities have internal states, birth, age and death (i.e. ages structure). Interactions between different entities will stochastically change the internal state of one or both the interacting entities. Space changes in the system are achieved with diffusion instead of collision.
It is worth to note that in the microscopic cellular framework one is interested only in the initial and final state. The model of the mechanisms which produce the change of state is deferred to subcellular models.
The model we describe here is driven by the experimental data on Triplex, an engineered vaccine for mammary carcinoma tested on HER-2/neu transgenic mice. Standard vaccines against viruses induce the primary response of the adaptive components of the Immune System against the nonself antigen in order to activate the Immune System memory which will then elicit the much stronger secondary response when the antigen will enter the body. The Immune System recognition of the antigen does not need to be stimulated as the antigen is a non self. At variance tumor vaccine need to stimulate the recognition of the TAA that otherwise would be treated as self and not attacked by the Immune System. Triplex is a vaccine engineered to perform this action using three components:
1. the TAA of the specific tumor (p185); 2. the allogenic MHCI molecule which allows a broad (polyclonal) stimulation of T and NK cells;
IL-2 and IL-12 whose action is to stimulate the Helper T cells.
The Immune competition is driven by the standard Immune System components responsible for the adaptive immunity, i.e. cells: B lymphocyte (B), T helper lymphocyte (Th), T killer (cytotoxic) lymphocyte (TC), Macrophage (MP), Plasma cell lymphocyte (PLB); and the molecules: antigen (bacteria or generic virus) (Ag), antibody (Ab) and immune complexes or Ab-Ag binding (IC). Moreover one need to represent some intracellular signals like, for example, interferon-gamma (IFN) and danger signal (D), and cytokines, interleukin-2 and interleukin-12.
Moreover a small action against tumor cell is performed also from components of the innate Immune System, mainly Natural Killer, NK, which are also included in the model. Finally we simulated the dynamic of the tumor cell population, CC, using probabilistic law to mimic the transition of the cell from the normal state to the progressing state (tumor cell). Cells in the progressing state then duplicate according to a specified probabilistic rule. Probabilistic rules are chosen in order to fit the experimental data for untreated mice.
From the computational point of view the major difference between cellular and molecular entities is that cells have a state attribute and may be classified on the basis of these attributes. Entities with no biological state, like TAA and antibodies are not followed individually but we consider only their total number for each lattice point. Their age structure is obtained increasing or decreasing the population number. The state of a cell is an artificial label introduced by the logical representation of the cells' behavior.
A DETAILED PRESENTATION OF THE MODEL IS GIVEN ELSEWHERE [31]
We summarize all the entities we take into the model and their different biological states in Table 1 . The interactions between entities are shown in Table 2 .
In Silico Experiments of Mouse Vaccination
In immunoprevention the vaccine action needs to be efficient in the very first appearance of the tumor cells. Those vaccines are not designed, and then not effective, if a solid tumor is already established. The vaccine action is to induce an immune response that controls the number of tumor cells and therefore prevents the development of a solid tumor mass. A successful vaccination schedule should then be able to prevent the formation of the solid tumor for the entire lifetime. In vivo experiments have been carried out on different statistical samples of HER-2/neu transgenic mice using four different vaccination schedules: Early, Late, Very Late, Chronic. These experiments measure the time at which a solid tumor is detected in each mouse.
A vaccination schedule is performed with three cycles of four intraperitoneal administration of non-replicanting vaccine cells over two weeks followed by two weeks of rest. The successful schedule is obtained when vaccination scheme starts at 6 weeks of age and continues for at least one year. Other schedules with only three cycles have been tried: The Early vaccination starting at the same age of 6 weeks, the Late, starting at 10 weeks and the Very Late starting at 16. The tumor growth in untreated mice has been analyzed for comparison. In order to analyze the effects of the different vaccine components, these experiments have been repeated, for the chronic schedule, with a modified vaccine in which different vaccine components were included. These experiments show that each single component is essential for the vaccine effectiveness, i.e. if one component is absent all the mice develop at least one tumor despite continuing vaccinations. However the time of solid tumor development can slightly change.
Taking into account the number of simulated Immune System entities in the lattice we decided that a solid tumor is formed in the grid when the number of cancer cells in the lattice becomes greater than 10 5 . The simulation is then stopped and the development time of solid tumor is recorded.
In silico experiments have been carried out using the standard statistical procedure: i) we considered a mice population of about 10 4 individuals mice (each individual mouse is characterized by a sequence of uniform numbers which will determine the probabilistic events); ii) we randomly extract from this population two statistical samples of 100 individual mice to perform the numerical experiments.
Computation proceeds from time t = 0, which correspond to a mouse age of 6 weeks, to time t = 72 weeks. The time step of the simulator is 8 hours.
All mice, in both statistical samples, have been treated with each of the schedules described above. Simulation stops when the solid tumor is formed and the time of solid tumor mass formation t* is recorded for each mouse.
The percentage of mice in which a solid tumor has grown as function of age is shown in Fig. (1) for one of the in silico experiments (100 mice). This is in good agreement with in vivo experiments [32] . The behavior of other statistical experiments is similar.
The simulation allows us to record the evolution of all populations entities as function of space and time. The Immune response elicited by the vaccine can be better shown if we consider the total number of immune cells in the lattice as function of time. Not surprisingly this behaviour is rather similar for all mice which undergo the same treatment and develop a solid tumor roughly at the same time. Figs. (2) and (3) show the number of Cancer Cells, Tumor Associated antigens, Cytotoxic T cells and Antibodies versus time in a mouse treated with the Early and the Chronic schedules. We point out that while Cytotoxic cells are responsible for the initial decreasing of the number of cancer cells, the humoral response is keeping this number under control. We notice that the spatial distribution of Cancer cells is initially randomly distributed and then leads to the formation of aggregates, as one would expect when newly formed Cancer cells locally duplicate. A detailed discussion of the above results can be found in [27] . Fig. (2) . Early.
Hereon we show preliminary results of a new set of insilico experiments we have performed in order to analyse the effect of the vaccine components. In order to analyse the effect of all the vaccine components the model described above needs to be slightly modified. However with the present model we are able to preliminary evaluate the action of the vaccine in the following situations: i) vaccine without the allogenic MHCI molecule, ii) vaccine without allogenic MHCI molecule and Interleukin 12 cytokine, iii) vaccine without Interleukin-12 cytokine and TAA (p185).
The effect of the above modification of the vaccine composition can be better appreciated comparing the plot of Cancer cells, Cytotoxic T cells, Antibodies, Tumor Associated Antigens versus time for a complete vaccine and the three modified vaccines. This is shown in Figs. (4, 5, 6 ) and (7).
As found in the in vivo experiments all vaccine's components are crucial for the mouse survival in chronic schedule. The presence of Allogenic MHCI looks to be crucial in stimulating the cellular response while it is not relevant for the humoral response. The humoral response is triggered by Fig. (3) . Chronic. the presence of Tumor associated antigens (p185) in the vaccine as shown clearly in Fig. (6) . A detailed analysis of the vaccine components on the development of solid tumor requires the investigation of all possible combinations. This work, which needs improving the model's biological details, is still in progress and results will be given in due course.
DNA MICROARRAYS IN TUMOR IMMUNOLOGY
A major problem in tumor immunology is the evaluation of the immunological response during cancer immunotherapy. The evaluation of cytotoxic chemotherapy is straightforward because tumor regression is directly induced by treatment. In contrast, immunological treatments aimed at activating the endogenous immune response usually do not directly affect tumor cells. Therefore, if a given treatment does not block tumor growth, the reason could be either that the treatment does not induce the desired immune response, or that the immune response does not affect tumor growth. Moreover the evaluation of induced immune responses is complicated by practical and theoretical issues. For practical reasons samples are usually taken from the peripheral blood of patients, but antitumor immune responses, with a few exceptions, take place in the lymphnode or within tumor lesions, not in blood. A further problem is the choice of immune responses to monitor. Nowadays we have thousands of different tests potentially relevant to tumor immunity, ranging from antigen expression, to cytokines and chemokines, to cellular and humoral activities, and it is virtually impossible to apply each test to every patient. A possible solution to the problems outlined above comes from DNA microarrays, a convenient system to simultaneously measure the transcription level of thousands of genes, up to the entire transcriptome of any given cell or tissue. The major advantage of microarrays is that the investigator is not limited to a small set of predefined genes to evaluate, and the analysis of the entire transcriptome can reveal hidden pathways activated or inhibited by immune responses and by immunotherapy.
We have recently completed a microarray study of the genes activated in the mammary gland of HER-2 transgenic mice during progression from hyperplasia to carcinoma, and in mice receiving an immunopreventive treatment [5, 6, 32] . We found two types of interesting results. First, the genes and the immune response patterns shown by microarray analysis perfectly mirrored the results of more conventional immunological, morphological and immunohistochemical studies, thus confirming that in this immunopreventive protocol antibodies and -interferon were the dominant immune responses elicited by the vaccine [33] [34] [35] , and that vaccination "froze" mammary transcriptome at a preneoplastic stage, effectively blocking the expression of many genes related to the development of mammary carcinoma. These results are shown in Fig. (8) , in which each lane represents a gene, and each column a sample; the first three clusters group the genes expressed by tumor cells (boxes on the left) and downregulated by vaccination, while the last three contain those switched on by the immunopreventive treatment, mainly represented by immunoglobulin chains and interferon-induced genes (boxes on the right).
The added value of microarray studies of the immune response was the discovery that the immune response unexpectedly activated genes related to mammary cell biology, a point that will deserve further experimental investigation [21] . The second added value is that, by monitoring both the achievement and the failure of immune prevention it is possible to pinpoint not only the genes induced by the immune reaction, but also those silenced by it. This kind of analysis cannot be performed by conventional immunological techniques. This is particularly important as cancer immunology is now facing the problem to identify new tumor antigens that can be targets of effective immune prevention or immunotherapeutic strategies. Overexpressed genes in cancer can be identified by gene expression profiling and the immunogenic epitopes can be predicted and then directly tested by conventional immunological techniques. This approach of "reverse immunology" will probably be a valuable tool to identify new tumor antigens. With the increasing number of tumor types and murine models analyzed with microarrays it will be possible to identify common molecules for immunological targeting. Talking in a more general way, what microarrays can give us is a wider vision on tumor development and on tumor-host interactions, amplifying on an exponential scale the number of new hypotheses and new experiments to be tested.
The use of DNA microarrays for the analysis of human tumors yielded very interesting results for the molecular classification of tumor subtypes in relation to prognosis, and further results are expected in the near future for what concerns prediction of response to therapy [36] [37] [38] [39] [40] . The first studies of tumor samples to elucidate the immune response of human patients to immunotherapy produced promising results [41] .
Future developments of DNA microarrays in oncology and in tumor immunology face various challenges that will involve immunoinformatics, technology, and immunology. The first question deals with the analysis of results. The novelty of microarrays and the huge number (for biological standards) of numeric data produced by experiments prompted the development of many independent algorithms and strategies to analyze results. We think that in the future the microarray community will need to concentrate on a reduced number of tested and true algorithms and software tools to analyze results. A perhaps related issue is that the expression profile of a complex sample composed of different cell types as can be a tumor infiltrated by immune and stromal cells will show the genes expressed by the different cell types all together. The goal will be to try to rebuild the tridimensional complexity of the in vivo tissue from a somehow 2-dimensional snapshot of the transcriptome, as microarray results can be thought of. An help to solve this problem will come from the daily increase in the number of publicly available data from tissues and cell lines that can in principle be combined to extract information from every cell type. The second issue, that stems from this final consideration, regards microarray technology itself. There are several methods to make DNA microarrays and to analyze biological samples, altogether referred to as "technological platforms". While each platform is reliable and yields internally consistent results, interplatform comparisons could lead to consensus signatures [42] . A discussion of the explanations and possible remedies of this state of facts goes beyond the scope of the present paper, but it is quite evident that standardization and improved interplatform consistency will be major issues in deciding the acceptance of DNA microarrays in the clinical environment.
Finally, for what concerns tumor immunology, microarrays have not solved the problem of sampling described at the beginning of this paragraph. Current results were obtained from tumor samples, which are a rational, but unpractical way of studying the immune response to tumor in patients. We know now that, with most conventional immunological techniques, sampling the peripheral blood to understand what is taking place at the tumor level does not yield meaningful results [36] . The challenge for microarrays, and for other technologies such as proteomics, will be to overcome this hurdle and to demonstrate their potency in extracting meaningful information where conventional immunological techniques have failed.
CONCLUSIONS
The fundamental problem of tunnel immunology, and of immunology at large, is complexity. Intrinsic complexity of the immune system and of its relations with tumor and pathogens is compounded by external perturbations in the form of therapeutic or preventive interventions aimed at improving anti-tumor immunity. Understanding complexity is of paramount importance both to address failures in our interventions and in dissecting the mechanisms responsible for our successes. We have discussed here two immunoinformatic approaches, mathematical models and analysis of DNA microrarray data, to rationally address the complexity of tumor immunology. It is hoped had a wider adoption of these and other immunoinformatic approaches will lead to a better understanding of tumor-host relationships and ultimately to more effective immunological solutions to cure cancer.
